Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2009 Jun 15;15(12):3970-7. doi: 10.1158/1078-0432.CCR-08-2786. Epub 2009 Jun 9.

Rational combinations using HDAC inhibitors.

Author information

  • 1Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, East Melbourne Victoria, Australia.

Abstract

In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs. In numerous in vitro and preclinical settings, these compounds have shown their vast potential as single agent anticancer therapies, but unfortunately equivalent responses have not always been observed in patients. Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs. In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong molecular rationale.

PMID:
19509171
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk